Raras
Buscar doenças, sintomas, genes...
Síndrome de King-Denborough
ORPHA:99741CID-10 · G71.2CID-11 · 8C72.YOMIM 619542DOENÇA RARA

Miopatia genética não distrófica rara caracterizada pela tríade de miopatia congênita, características dismórficas e suscetibilidade à hipertermia maligna. Os pacientes apresentam uma ampla gama fenotípica, incluindo atraso no desenvolvimento motor, fraqueza muscular e fadiga, ptose e fácies miopática (com ou sem elevações de creatina quinase), anormalidades esqueléticas (por exemplo, baixa estatura, escoliose, cifose, lordose lombar e pectus carinatum/excavatum), características faciais dismórficas leves (por exemplo, hipertelorismo, fissuras palpebrais inclinadas para baixo, dobras epicânticas, orelhas de inserção baixa, micrognatia), membrana do pescoço, criptorquidia e suscetibilidade a hipertermia maligna e/ou rabdomiólise devido a esforço físico intensivo, infecção viral ou uso de estatinas.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Miopatia genética não distrófica rara caracterizada pela tríade de miopatia congênita, características dismórficas e suscetibilidade à hipertermia maligna. Os pacientes apresentam uma ampla gama fenotípica, incluindo atraso no desenvolvimento motor, fraqueza muscular e fadiga, ptose e fácies miopática (com ou sem elevações de creatina quinase), anormalidades esqueléticas (por exemplo, baixa estatura, escoliose, cifose, lordose lombar e pectus carinatum/excavatum), características faciais dismórficas leves (por exemplo, hipertelorismo, fissuras palpebrais inclinadas para baixo, dobras epicânticas, orelhas de inserção baixa, micrognatia), membrana do pescoço, criptorquidia e suscetibilidade a hipertermia maligna e/ou rabdomiólise devido a esforço físico intensivo, infecção viral ou uso de estatinas.

Publicações científicas
18 artigos
Último publicado: 2026 Feb 10

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
<1 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Casos conhecidos
18
pacientes catalogados
Início
Antenatal
+ infancy, neonatal
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: G71.2
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

💪
Músculos
8 sintomas
🦴
Ossos e articulações
6 sintomas
😀
Face
5 sintomas
👁️
Olhos
2 sintomas
🧠
Neurológico
1 sintomas
👂
Ouvidos
1 sintomas

+ 17 sintomas em outras categorias

Características mais comuns

100%prev.
Ptose bilateral
Obrigatório (100%)
100%prev.
Fácies miopática
Obrigatório (100%)
100%prev.
Escoliose
Obrigatório (100%)
100%prev.
Movimento fetal diminuído
Obrigatório (100%)
100%prev.
Fraqueza muscular proximal
Frequência: 5/5
100%prev.
Escafocefalia
Obrigatório (100%)
42sintomas
Muito frequente (24)
Frequente (15)
Ocasional (2)
Sem dados (1)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 42 características clínicas mais associadas, ordenadas por frequência.

Ptose bilateralBilateral ptosis
Obrigatório (100%)100%
Fácies miopáticaMyopathic facies
Obrigatório (100%)100%
EscolioseScoliosis
Obrigatório (100%)100%
Movimento fetal diminuídoDecreased fetal movement
Obrigatório (100%)100%
Fraqueza muscular proximalProximal muscle weakness
Frequência: 5/5100%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico18PubMed
Últimos 10 anos8publicações
Pico20232 papers
Linha do tempo
2026Hoje · 2026
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal dominant.

RYR1Ryanodine receptor 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Cytosolic calcium-activated calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytosol and thereby plays a key role in triggering muscle contraction following depolarization of T-tubules (PubMed:11741831, PubMed:16163667, PubMed:18268335, PubMed:18650434, PubMed:26115329). Repeated very high-level exercise increases the open probability of the channel and leads to Ca(2+) leaking into the cytoplasm (PubMed:18268335). Can also mediate the release of Ca(2+)

LOCALIZAÇÃO

Sarcoplasmic reticulum membrane

VIAS BIOLÓGICAS (2)
Ion homeostasisStimuli-sensing channels
MECANISMO DE DOENÇA

Malignant hyperthermia 1

Autosomal dominant pharmacogenetic disorder of skeletal muscle and is one of the main causes of death due to anesthesia. In susceptible people, an MH episode can be triggered by all commonly used inhalational anesthetics such as halothane and by depolarizing muscle relaxants such as succinylcholine. The clinical features of the myopathy are hyperthermia, accelerated muscle metabolism, contractures, metabolic acidosis, tachycardia and death, if not treated with the postsynaptic muscle relaxant, dantrolene. Susceptibility to MH can be determined with the 'in vitro' contracture test (IVCT): observing the magnitude of contractures induced in strips of muscle tissue by caffeine alone and halothane alone. Patients with normal response are MH normal (MHN), those with abnormal response to caffeine alone or halothane alone are MH equivocal (MHE(C) and MHE(H) respectively).

EXPRESSÃO TECIDUAL(Tecido-específico)
Músculo esquelético
423.5 TPM
Cerebelo
21.3 TPM
Cérebro - Hemisfério cerebelar
15.4 TPM
Hipotálamo
13.6 TPM
Testículo
8.7 TPM
OUTRAS DOENÇAS (13)
King-Denborough syndromecongenital multicore myopathy with external ophthalmoplegiacentral core myopathymalignant hyperthermia, susceptibility to, 1
HGNC:10483UniProt:P21817

Variantes genéticas (ClinVar)

6,385 variantes patogênicas registradas no ClinVar.

🧬 RYR1: NM_000540.3(RYR1):c.1456del (p.Val486fs) ()
🧬 RYR1: NM_000540.3(RYR1):c.14555A>C (p.Tyr4852Ser) ()
🧬 RYR1: NM_000540.3(RYR1):c.7061T>C (p.Val2354Ala) ()
🧬 RYR1: NM_000540.3(RYR1):c.528G>C (p.Glu176Asp) ()
🧬 RYR1: NM_000540.3(RYR1):c.5011_5048del (p.Ala1671fs) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

2 vias biológicas associadas aos genes desta condição.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Síndrome de King-Denborough

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
8 papers (10 anos)
#1

The Clinical, Histological, and Genetic Spectrum of RYR1 Variants-A Multi-Center Israeli Cohort Study.

Journal of clinical medicine2026 Feb 10

Background: Variants in the ryanodine receptor 1 (RYR1) gene have been linked to a range of disorders, from congenital myopathy to adult-onset manifestations, with phenotypes varying from mild to severe. Methods: A retrospective review was conducted on an Israeli cohort of 36 individuals with RYR1 variants, identified through genetic testing as part of a national collaboration among multiple pediatric and adult neuromuscular clinics. Clinical features, molecular data, laboratory results, electromyographic findings, and muscle histology were analyzed. Each variant was classified according to its respective domain within the RYR1 gene. Results: Thirty-six cases were included in the analysis; 31 were from 11 unrelated families, and 5 were sporadic. Nine individuals were asymptomatic with normal CK levels. Most of the 27 affected patients presented with variable degrees of perinatal weakness, often accompanied by respiratory impairment or arthrogryposis. Weakness was predominantly proximal, with clinical courses that included deterioration, improvement, or stabilization. Three cases of King-Denborough syndrome were identified. Additional presentations included malignant hyperthermia and, in isolated cases, periodic paralysis. Muscle biopsies demonstrated considerable histologic heterogeneity, including fiber-size variation, internal nuclei, multiminicores, and fibrosis or dystrophic features. The pathogenic RYR1 variants included five compound-heterozygous genotypes, two homozygous variants, and two heterozygous variants. There was a positive correlation between variants located in the Bsol domain and disease severity. Conclusions: This cohort confirms and expands the clinical and histological diversity associated with RYR1 variants in Israel. Variants in the Bsol domain appear to be indicative of disease severity.

#2

Biallelic variants in RYR1 and STAC3 are predominant causes of King-Denborough Syndrome in an African cohort.

European journal of human genetics : EJHG2025 Apr

King-Denborough Syndrome (KDS) is a congenital myopathy (CM) characterised by myopathy, dysmorphic features and susceptibility to malignant hyperthermia. The objective of this study was to investigate the genotype-phenotype correlation in Black African patients presenting with CM, specifically those with KDS-like phenotypes, who remained undiagnosed for over 25 years. A cohort of 67 Black African patients with CM was studied, of whom 44 were clinically evaluated and diagnosed with KDS. Whole-exome sequencing (WES) was performed as part of an international genomics study (ICGNMD) to identify potential pathogenic mutations. Genomic assessments focused on identifying relevant genes, including RYR1 and STAC3, and establishing genotype-phenotype correlations. The study identified RYR1 and STAC3 mutations as the predominant genetic causes of KDS in this cohort, with mutations in both genes exhibiting autosomal recessive inheritance. While RYR1 has previously been linked to autosomal dominant mutations, STAC3, which was formerly associated exclusively with Native American Myopathy/Bailey-Bloch Myopathy, congenital hypotonia, and susceptibility to malignant hyperthermia, is now newly associated with CM-KDS in this study. This establishes the first genotype-phenotype correlation for 44 Black African individuals with KDS. This study marks a significant milestone in research on understudied African populations with CM, emphasising the lengthy diagnostic journey these patients endured. The findings highlight the pressing need for improved access to genomic medicine in underserved regions and underscore the importance of expanding research and diagnostic capabilities in Africa. This work contributes to the advancement of genetic medicine in underrepresented populations, facilitating better diagnostic and therapeutic outcomes.

#3

Pancreatitis in RYR1-related disorders.

Neuromuscular disorders : NMD2023 Oct

Mutations in RYR1 encoding the ryanodine receptor (RyR) skeletal muscle isoform (RyR1) are a common cause of inherited neuromuscular disorders. Despite its expression in a wide range of tissues, non-skeletal muscle manifestations associated with RYR1 mutations have only been rarely reported. Here, we report three patients with a diagnosis of Central Core Disease (CCD), King-Denborough Syndrome (KDS) and Malignant Hyperthermia Susceptibility (MHS), respectively, who in addition to their (putative) RYR1-related disorder also developed symptoms and signs of acute pancreatitis. In two patients, episodes were recurrent, with severe multisystem involvement and sequelae. RyR1-mediated calcium signalling plays an important role in normal pancreatic function but has also been critically implicated in the pathophysiology of acute pancreatitis, particularly in bile acid- and ethanol-induced forms. Findings from relevant animal models indicate that pancreatic damage in these conditions may be ameliorated through administration of the specific RyR1 antagonist dantrolene and other compounds modifying pancreatic metabolism including calcium signalling. These observations suggest that patients with RYR1 gain-of-function variants may be at increased risk of developing acute pancreatitis, a condition which should therefore be considered in the health surveillance of such individuals.

#4

A novel RYR1 variant in an infant with a unique fetal presentation of central core disease.

American journal of medical genetics. Part A2023 Jun

Ryanodine receptor type 1-related disorder (RYR1-RD) is the most common subgroup of congenital myopathies with a wide phenotypic spectrum ranging from mild hypotonia to lethal fetal akinesia. Genetic testing for myopathies is imperative as the diagnosis informs counseling regarding prognosis and recurrence risk, treatment options, monitoring, and clinical management. However, diagnostic challenges exist as current options are limited to clinical suspicion prompting testing including: single gene sequencing or familial variant testing, multi-gene panels, exome, genome sequencing, and invasive testing including muscle biopsy. The timing of diagnosis is of great importance due to the association of RYR1-RD with malignant hyperthermia (MH). MH is a hypermetabolic crisis that occurs secondary to excessive calcium release in muscles, leading to systemic effects that can progress to shock and death if unrecognized. Given the association of MH with pathogenic variants in RYR1, a diagnosis of RYR1-RD necessitates an awareness of medical team to avoid potentially triggering agents. We describe a case of a unique fetal presentation with bilateral diaphragmatic eventrations who had respiratory failure, dysmorphic facial features, and profound global hypotonia in the neonatal period. The diagnosis was made at several months of age, had direct implications on her clinical care related to anticipated need to long-term ventilator support, and ultimately death secondary an arrhythmia as a result of suspected MH. Our report reinforces the importance of having high suspicion for a genetic syndrome and pursuing early, rapid exome or genome sequencing as first line testing in critically ill neonatal intensive care unit patients and further evaluating the pathogenicity of a variant of uncertain significance in the setting of a myopathic phenotype.

#5

Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.

Skeletal muscle2020 Nov 16

The RYR1 gene, which encodes the sarcoplasmic reticulum calcium release channel or type 1 ryanodine receptor (RyR1) of skeletal muscle, was sequenced in 1988 and RYR1 variations that impair calcium homeostasis and increase susceptibility to malignant hyperthermia were first identified in 1991. Since then, RYR1-related myopathies (RYR1-RM) have been described as rare, histopathologically and clinically heterogeneous, and slowly progressive neuromuscular disorders. RYR1 variants can lead to dysfunctional RyR1-mediated calcium release, malignant hyperthermia susceptibility, elevated oxidative stress, deleterious post-translational modifications, and decreased RyR1 expression. RYR1-RM-affected individuals can present with delayed motor milestones, contractures, scoliosis, ophthalmoplegia, and respiratory insufficiency.Historically, RYR1-RM-affected individuals were diagnosed based on morphologic features observed in muscle biopsies including central cores, cores and rods, central nuclei, fiber type disproportion, and multi-minicores. However, these histopathologic features are not always specific to RYR1-RM and often change over time. As additional phenotypes were associated with RYR1 variations (including King-Denborough syndrome, exercise-induced rhabdomyolysis, lethal multiple pterygium syndrome, adult-onset distal myopathy, atypical periodic paralysis with or without myalgia, mild calf-predominant myopathy, and dusty core disease) the overlap among diagnostic categories is ever increasing. With the continuing emergence of new clinical subtypes along the RYR1 disease spectrum and reports of adult-onset phenotypes, nuanced nomenclatures have been reported (RYR1- [related, related congenital, congenital] myopathies). In this narrative review, we provide historical highlights of RYR1 research, accounts of the main diagnostic disease subtypes and propose RYR1-related disorders (RYR1-RD) as a unified nomenclature to describe this complex and evolving disease spectrum.

Publicações recentes

Ver todas no PubMed

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Síndrome de King-Denborough.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Síndrome de King-Denborough

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. The Clinical, Histological, and Genetic Spectrum of RYR1 Variants-A Multi-Center Israeli Cohort Study.
    Journal of clinical medicine· 2026· PMID 41753076mais citado
  2. Biallelic variants in RYR1 and STAC3 are predominant causes of King-Denborough Syndrome in an African cohort.
    European journal of human genetics : EJHG· 2025· PMID 39966651mais citado
  3. Pancreatitis in RYR1-related disorders.
    Neuromuscular disorders : NMD· 2023· PMID 37783627mais citado
  4. A novel RYR1 variant in an infant with a unique fetal presentation of central core disease.
    American journal of medical genetics. Part A· 2023· PMID 36965156mais citado
  5. Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.
    Skeletal muscle· 2020· PMID 33190635mais citado

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:99741(Orphanet)
  2. OMIM OMIM:619542(OMIM)
  3. MONDO:0020485(MONDO)
  4. GARD:8433(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q56014439(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Síndrome de King-Denborough
Compêndio · Raras BR

Síndrome de King-Denborough

ORPHA:99741 · MONDO:0020485
Prevalência
<1 / 1 000 000
Casos
18 casos conhecidos
Herança
Autosomal dominant
CID-10
G71.2 · Miopatias congênitas
CID-11
Início
Antenatal, Infancy, Neonatal
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C1840365
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades